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Abstract
Background: Herpes simplex virus type-1 (HSV-1) has been described to cause respiratory tract
infections in critically ill patients or in individuals that are immunocompromised. It is a continuing
matter of debate under which circumstances HSV-1 is a relevant pathogen for pneumonitis. While
its role during critical illness has been investigated by prospective interventional studies,
comparatively little systematic data is available on the role of HSV-1 for pneumonitis in outpatients
with autoimmune disease under a maintenance regimen of immunosuppression.
Methods: We retrospectively reviewed the charts of ~1400 patients with rheumatoid arthritis,
vasculitis, and systemic lupus erythematosus (SLE) that were followed at the outpatient clinic of a
German University hospital during the years 2000–2007. Episodes of admission to a ward resulting
in the diagnosis of pneumonia/pneumonitis were identified, and the type of pneumonia and clinical
features retrospectively studied.
Results: 63 patients with rheumatoid arthritis, vasculitis, or SLE were admitted to a ward and
diagnosed to have pneumonia/pneumonitis. Using bronchoscopy a total of 6 cases of pulmonary
infection associated with HSV-1 in the lower respiratory tract were identified. Among those, 2
cases suggested a causative role of HSV-1 as the sole agent causing pneumonitis that proved
clinically responsive to antiviral treatment. In the remaining 4 cases HSV-1 appeared as a bystander
of bacterial infection. Maintenance therapy with leflunomide, which inhibits HSV-1 assembly in vitro,
was associated with a milder course of pneumonitis in one patient. Detection of HSV-1 was
associated with stronger immunosuppressive regimens and vasculitic disease.
Conclusion: The present study analyzed the frequency and hallmarks of cases of HSV-1 associated
pneumonitis that occurred in a comparatively large cohort of patients with rheumatologic
autoimmune diseases. In an area of controversy, this study provides further evidence that HSV-1
causes isolated pneumonitis in the immunocompromised. The study may provide an estimate on
the frequency of relevant HSV-1 infection and bacterial agents in outpatients with autoimmune
disease.
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Background
After reactivation from latency in facial nerve ganglia, her-
pes simplex virus type-1 (HSV-1) may cause tracheobron-
chitis or pneumonitis featuring life-threatening
respiratory-failure with bilateral changes on thoracic
imaging [1-4]. HSV-1 pneumonitis is comparatively well
investigated in critically ill patients under mechanical ven-
tilation, where ~90% show an oropharyngeal reactivation
of the virus within the first 10 days [5]. In a number of
retro- and prospective studies in this setting presence of
cytology-proven HSV-1 pneumonitis was shown to have a
poorer outcome, but antiviral treatment was not benefi-
cial [6-9]. Immunosuppressed patients with malignan-
cies, organ transplants, and cytotoxic treatments for
various reasons are the other large, though extremely het-
erogeneous, group of patients that have been described to
develop HSV-1 pneumonitis. Data on the disease in these
subjects is more scarce and mainly consists of anecdotal
accounts [10-16]. Only one retrospective study of bron-
choalveolar lavage (BAL) microbiology/virology results
from renal transplant patients is available and, very
recently, a retrospective study on HSV-1 pneumonitis in
patients with solid tumors was published representing the
first systematic approaches in the field [17,18]. In view of
lack of data, it was the goal of the present study to investi-
gate the potential significance of HSV-1 pneumonitis in
patients under a maintenance regimen of ambulatory
immunosuppression. We therefore retrospectively ana-
lyzed admissions for pneumonia/pneumonitis in a com-
paratively large cohort of outpatients with rheumatoid,
vasculitic and connective tissue autoimmune disease over
a period of 8 years.
Methods
This retrospective study was approved by the local Ethics
Committee. The local electronic database containing all
patient diagnoses and discharge summaries of our rheu-
matologic outpatient clinic and the affiliated hospitals of
the Department of internal medicine were searched for a
combination of the terms of the rheumatologic/vasculitic/
connective tissue disease and pneumonia or pneumonitis.
Each episode of a positive hit was reviewed. Severity of
current immunosuppressive treatment was scored 0–4 as
follows: 0 = no immunosuppressive medication; 1 = low-
dose: (prednisone ≤ 10 mg/d) or (azulfidine/chloro-
quine); 2 = intermediate: (prednisone 20–40 mg/d) or
(prednisone 10 mg/d+methotrexate) or (prednisone 10
mg/d+leflunomide) or (cyclosporine) or (pred-
nisone+mycophenolate mofetil) or (prednisone 20 mg/
d+azathioprine); 3 = strong: (prednisone 40 mg/d+meth-
otrexate) or (prednisone 20 mg/d+methotrexate+anak-
inra) or (prednisone 20 mg/
d+methotrexate+leflunomide) or (prednisone 20 mg/
d+etanercept) or (prednisone 40 mg/d+azathioprine) or
(lower dose prednisone+azathioprine+leukopenia); 4 =
maximal: (prednisone 60 mg/d+cyclophosphamide) or
(prednisone 100 mg/d).
At the time of in-hospital treatment the patients were
diagnosed and treated by current standards of clinical
practice and were not part of a prospective clinical trial
regarding the treatment of pneumonia or pneumonitis.
Fiberoptic bronchoscopy (FOB) was performed when
deemed appropriate. Bronchoalveolar lavage (BAL) was
performed with each bronchoscopic examination and
material was subsequently centrifuged, fixated in 4%
paraformaldehyde and stained using hematin-eosin.
Standard microscopic examination was performed. BAL
fluids were also subjected to viral polymerase chain reac-
tion (PCR) when deemed appropriate that always con-
sisted of testing for HSV-1 and CMV (cytomegaly virus). In
selected positive cases immunohistochemistry of BAL for
HSV-1 was performed using a rabbit polyclonal antibody
against HSV-1 (DAKO Laboratories, Denmark). Broncho-
scopic biopsies were performed when deemed appropri-
ate and processed using standard protocols.
Microbiologic and serologic diagnostics were performed
using standard protocols.
Statistical analysis was performed using Prism 4 software
(Graph Pad, La Jolla, CA).
Results
As it is unclear to which extent an outpatient regimen of
current standard immunosuppression for autoimmune
disease may confer a risk for HSV-1 pneumonitis, we ret-
rospectively reviewed the charts of ~1400 patients with
rheumatoid arthritis (~1000), ANCA-associated vasculitis
(~80), and systemic lupus erythematosus (SLE) (~320)
that were followed during the years 2000–2007 in the
nephrology and rheumatology outpatient clinic at the
Medical Policlinic, LMU University of Munich. During the
study period 766 ward-admissions of patients with rheu-
matologic/vasculitic/connective tissue autoimmune dis-
ease occurred. Among those there were 63 (8%) episodes
of admission from 63 outpatients of our clinic presenting
with respiratory deterioration that were ultimately diag-
nosed to be due to pneumonia or pneumonitis (Table 1).
As a rough estimate one can infer an incidence of commu-
nity-acquired respiratory infection or pneumonitis requir-
ing hospitalization in outpatients with autoimmune
disease of [63 patients * 100/(1400 patients *8 years)],
i.e., ~0.5% per year.
In 23 of these 63 patients bronchoscopy with lavage was
performed for diagnostic purposes within the first four
days of admission, which in 14 (61%) also comprised
PCR analysis for HSV-1. Thereby a total of six patients
(10% of admissions for pneumonia) with positive HSV-1BMC Pulmonary Medicine 2009, 9:22 http://www.biomedcentral.com/1471-2466/9/22
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DNA detection in alveolar fluids was identified. In order
to estimate the degree of immunosuppressive strength in
the patient population, an arbitrary score ranging form
0–4 was applied (see methods).
Relevant clinical, imaging and laboratory data on the six
patients with a positive HSV-1 DNA detection on BAL are
summarized in Table 2.
Two cases (Case 1 and 2) in which no other viral, bacterial
or fungal agent than HSV-1 on BAL PCR was found and in
which imaging studies were suggestive for HSV-1 pneu-
monitis were successfully treated with acyclovir leading to
rapid clinical improvement. In both cases, the initial chest
radiograph and thoracic CT showed diffuse infiltrations or
ground glass opacities. Representative images are shown
in Figure 1A, B. HSV-1 infection may feature a macroscop-
ically vulnerable aspect of the bronchial mucosa as a non-
specific sign (Figure 1C). In order to increase diagnostic
certainty in Case 2, immunohistochemical staining of
bronchioalveolar cells for HSV-1 was performed, which
proved positive (Figure 2). In both cases inclusion bodies
of epithelial cells from BAL were present. Our diagnosis in
Case 1 and 2 was isolated HSV-1 pneumonitis, which was
supported by the response to acyclovir in the absence of
prolonged antibacterial treatment.
Case 3 and 4 displayed an initial co-infection with fungal
or bacterial agents and HSV-1 and required prolonged
mechanical ventilation. Imaging studies were compatible
with viral pneumonitis, but in Case 4 infiltrates suggesting
bronchopneumonia were also clearly present. The
mucosa was macroscopically inflamed in both cases.
While Case 3 had inclusion bodies on cytology, such stud-
ies were not pursued in Case 4 due to obvious bronchop-
neumonia. Both patients had a fatal outcome after a
prolonged in-hospital stay despite adequate antiinfective
treatment that included timely administration of acyclo-
vir.
Cases 5 and 6 are different from the former four cases
therein that no bilateral groundglass opacities were
present on thoracic CT and no antiviral treatment was ini-
tiated. In Case 5, a high HSV-1 viral load from BAL fluids
was ignored given the detection of Influenza A virus with
S. aureus and Ps. aeruginosa. The patient improved on
antibacterial treatment alone and was discharged. He was
readmitted one month later with de-novo respiratory dete-
rioration that resulted in the need for intubation after the
administration of a series of antimicrobial courses that
always excluded acyclovir. CT and a second BAL now
showed ground glass opacities/ARDS and an even higher
HSV-1 viral load. The patient died from ARDS before anti-
viral treatment could be initiated. Case 6 featured an uni-
lateral bronchopneumonic infiltrate and was treated with
standard antibacterial regimens until Mycobacterium
kansasii grew from the initial BAL. Treatment was changed
accordingly and the patient recovered without the admin-
istration of antivirals.
In an area of controversy, the first two cases provide fur-
ther evidence that in selected patients, if ascertained to be
the sole agent, HSV-1 is a relevant pathogen of pneumo-
nitis that is amenable to treatment. Cases 3–6 reflect the
Table 1: Classification and clinical course of the study population, i.e., 63 patients with rheumatic/vasculitic or connective tissue disease 
admitted to hospital and diagnosed to have pneumonia/pneumonitis
Total 
admissions 
to hospital
Admissions 
for PNA (% 
of 
admissions)
FOB with 
BAL in 
PNA 
(% of PNA)
BAL-PCR 
for HSV-1 
and CMV 
(% of FOB)
Positive 
HSV-1 
BAL-PCR 
(% of PNA)
Requirement 
of intubation 
in PNA 
(% of PNA)
Mean and 
(median) 
age of 
patients 
with PNA 
in ys
Mean 
immuno-
suppression 
severity 
score of 
patients with 
PNA* 
Lethal 
outcome 
in PNA 
Wegener's 
Granulomatosis
74 13 (18%) 4 4 2 
(cases 3, 5)
26 6  ( 6 8 ) 3 . 3 2
Rheumatoid 
arthritis
515 34 (7%) 12 6 2 (cases 
1,4)
57 1  ( 7 4 ) 1 . 5 3
Polyangiits 22 4 (18%) 3 1 1 (case 2) 0 63 (64) 3.5 0
Systemic lupus 
erythematosus 
(SLE)
155 12 (8%) 4 3 1 (case 6) 1 53 (58) 1.6 1
total 766 63 (8%) 23 (37%) 14 (61%) 6 (10%) 8 (12%) 66 (66) 2.0 6 (10%)
Absolute numbers or percentages are given, (*) based on 56 of the 63 cases where information on immunosuppressive regimens was reliably 
available. In order to estimate the degree of immunosuppressive strength in the patient population, an arbitrary score ranging form 0–4 was applied 
(see methods). Abbreviations: BAL = bronchoalveolar lavage, FOB = fiberoptic bronchoscopy, PNA = pneumonia/pneumonitis, ys = years.BMC Pulmonary Medicine 2009, 9:22 http://www.biomedcentral.com/1471-2466/9/22
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Table 2: Synopsis of patient data on all cases with a positive HSV-1 result on PCR of bronchoalveolar lavage
Clinical data Case 1 Case 2 Case 3 Case 4 Case 5 Case 6
Age at presentation 
(yrs), gender
74, f 74, m 60, m 67, m 72, m 65, f
Rheumatological 
diagnosis 
(duration in years)
Rheumatoid 
arthritis, 
seronegative
8
pulmonary 
microscopic 
Polyangiitis
3
Wegener's 
Granulomatosis
2
Rheumatoid 
arthritis, 
seropositive
10
Wegener's 
Granulomatosis
8
Systemic lupus 
erythematosus
4
Co-Morbidities allergic asthma renal insufficiency diabetes, septic 
arthritis
HHT, renal 
insufficiency
Immunosuppression 
(severity score)
Pred 20 mg/d + 
MTX 15 mg/w + 
Lefl 20 mg/d (3)
Pred 50 mg/d + 
Cyclo 150 mg/d 
p.o.
(4)
Pred 20 mg/d 
+Cyclo 150 mg/d
(4)
Pred 20 mg/d + 
MTX 7.5 mg/w + 
Anakinra 100 mg/d 
(3)
Pred 40 mg/d + 
Cyclo 500 mg/m 
i.v.
(4)
Pred 20 mg/d + 
Aza 150 mg/d, 
pancytopenia
(3)
clinical presentation 
in the outpatient 
setting prior to 
admission
21 days of cough, 
fever
3 days of bloody 
cough, dysphagia
3 days of dyspnea, 
syncope
7 days of dyspnea, 
cough
5 days of dyspnea, 
cough, weakness
1 day of dyspnea, 
non-productive 
cough
Notable findings HSV-1 positive 
oral lesion
none HSV-1 positive 
oral lesion
none HSV-1 positive 
nasal lesion
none
Ventilatory support 
required
CPAP no intubation intubation no no
Radiological 
findings
Chest-XR diffuse bilateral 
ground-glass 
opacities
interstitial pattern interstitial pattern bilateral 
bronchopneumoni
c infiltrates with 
pleural effusions
bilateral 
bronchopneumoni
c infiltrates
unilateral infiltrate
High-resolution CT-
scan
diffuse bilateral 
ground-glass 
opacities
right-sided diffuse 
pleural effusions
diffuse bilateral 
ground-glass 
opacities 
(no granulomas)
extensive bilateral 
bronchopneumoni
c infiltrates with 
pleural effusions, 
atelectasis, hilar 
lymphadenopathy
diffuse bilateral 
granulomas
unilateral 
bronchopneumoni
c infiltrate
Bronchoscopy/
pathology
performed on 
hospital day
2 22224
Macroscopic 
mucosal aspect
Vulnerable, 
inflammamation
normal inflammation acute bronchitis vulnerable, acute 
bronchitis
vulnerable
BAL cytology: 
inclusion bodies
Positive positive positive n.a. n.a. n.a.
Lung biopsy Non-specific 
(chronic) 
bronchitis
n.p. non-specific 
fibroelastosis
n.p. n.p. n.p.
HSV-1 
immunohistology of 
BAL cytology or of 
lung biopsy
n.p. positive n.p. n.p. n.p. n.p.
Relevant 
identified 
infectious agents 
of pneumonia/
pneumonitis 
(from BAL)
HSV-1 as sole 
agent
HSV-1 as sole 
agent
Aspergillus, K. 
pneumoniae, HSV-
1
MRSA, P. 
aeruginosa, K. 
pneumoniae, HSV-
1
S. aureus, P. 
aeruginosa, 
Influenza A, HSV-1
S. aureus (coag 
neg), P. 
aeruginosa, 
Enterococci, HSV-
1, M. kansasii
Treatment - day 1: 
ceftriax+ery (for 
7 days; overlap 
with acyclo 5 
days)
- day 2: acyclo
- day 1: moxi 
(for 2 days)
- day 2: swap to 
acyclo 
monotherapy
- day 1: mero + 
ery + fluc
- day 2: add acyclo 
+ amphoB for fluc
- later: add cipro+ 
tobra + vanco for 
mero
sequential:
- ceftr+moxi
- genta+tazo+fluc
- mero
- vanc+linez
from day 2: acyclo
sequential:
- metro+clari 
+ceftriax
- day 3 ceftaz for 
ceftriax
sequential:
- 
clari+cipro+ceftaz
- fluc (for 14 days)
from day 14: INH+ 
rifampicin+ethamb
utolBMC Pulmonary Medicine 2009, 9:22 http://www.biomedcentral.com/1471-2466/9/22
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great difficulty of dissecting the role of HSV-1 in infections
with multiple pathogens [19] and illustrate that HSV-1
pneumonitis is a diagnosis of exclusion requiring a com-
plete microbiological workup. It remains speculative if
timely suppression of HSV-1 viral loads by antiviral treat-
ment in Case 5 would have altered the patient's course.
Outcome recovery after 7 
days
recovery after 11 
days
lethal after 28 days 
(ARDS)
lethal after 33 days 
(ARDS)
Initial recovery 
after 28 days, but 
lethal after 110 
days (ARDS) with 
persistant high 
HSV-1 viral load 
on BAL
recovery after 38 
days
Our Diagnosis/
comment
most likely 
isolated HSV-1 
pneumonitis
most likely 
isolated HSV-1 
pneumonitis
Bacterial, fungal 
and HSV-1 
pneumonia/
pneumonits
Bacterial 
bronchopneumoni
a with HSV-1 
reactivation
Bacterial 
pneumonia with 
untreated HSV-1 
reactivation. A 
second BAL PCR 
showed an 
increasing viral 
load
Mycobacteriosis 
due to M. kansasii 
(responsive to 
treatment). HSV-1 
reactivation 
without 
radiographic signs 
of pneumonitis 
that was not 
treated antivirally.
Complete 
microbiological 
work-up
Blood cultures negative negative negative negative negative negative
Mycobacteria 
culture/PCR BAL
negative negative negative negative negative positive 
(M. kansasii)
Aspergillus negative negative positive 
(serum Ag & 
culture)
negative n.p. negative 
(serum AG)
P. jirovecii BAL negative negative negative negative negative negative
MRSA culture 
Sputum
negative negative negative positive negative negative
P. aeruginosa 
culture BAL
negative negative negative positive positive positive
K. pneumoniae 
culture BAL
negative negative positive positive negative negative
M. pneumoniae negative 
(PCR BAL)
negative (serology) negative (serology) negative 
(PCR BAL)
negative 
(PCR BAL)
n.p.
C. trachomatis/
pneumoniae
negative 
(serology)
n.p. negative 
(PCR BAL)
negative 
(PCR BAL)
negative 
(PCR BAL)
negative 
(PCR BAL)
Legionella-Ag 
(Urine)
negative negative negative negative negative n.p.
Complete 
virological work-up
HSV-1 PCR BAL, 
Geq/ml
9.750.000 284.000 700.000 850.000 10.250.000 310.000
CMV-PCR BAL negative Negative negative negative negative negative
Influenza A PCR 
BAL* 
(season of 
presentation)
n.p. (May) n.p. (April) negative (January) n.p. (September) positive 
(February)
n.p. (June)
Adenovirus PCR 
BAL**
Negative negative negative n.p. n.p. n.p.
HIV-1/2-Ag ELISA n.p. n.p. negative n.p. Negative n.p.
Abbreviations used are: acyclo = acyclovir, Ag = antigen, amphoB = amphotericin B, ARDS = adult respiratory distress syndrome, Aza = 
azathioprine, BAL = bronchoalveolar lavage, ceftaz = ceftazidime, ceftriax = ceftriaxone, cipro = ciprofloxacin, clari = clarithromycin, CPAP = 
continuous positive airway pressure, CT = computed tomography, coag neg = coagulase negative, cyclo = cyclophosphamide, d = day, ery = 
erythromycin, fluc = fluconazole, genta = gentamycin, Geq/ml = genome equivalents/ml; HHT = hereditary hemorrhagic telangiectasia (Osler-
Weber-Rendu syndrome), INH = isoniazid, Lefl = leflunomide, linez = linezolid, mero = meropenem, metro = metronidazole, moxi = moxifloxacin, 
MTX = methotrexate, Pred = prednisone, tazo = piperacillin/tazobactam, tobra = tobramycin, vanco = vancomycin, w = week. *testing was 
seasonal during winter only. **testing was at the discretion of the physician performing bronchoscopy.
Table 2: Synopsis of patient data on all cases with a positive HSV-1 result on PCR of bronchoalveolar lavage (Continued)BMC Pulmonary Medicine 2009, 9:22 http://www.biomedcentral.com/1471-2466/9/22
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In the present study of 63 patients with autoimmune dis-
ease and pneumonia/pneumontis, no offending agent
could be found in 60% of cases. In the remaining 40% a
broad spectrum of bacteria, fungi and viruses was identi-
fied (Figure 3A). Of note, one case of pneumonitis was
due to methotrexate. Two cases (3.2%) were most likely
due to HSV-1, while HSV-1 was a bystander of other
agents in the remaining four cases.
When comparing the six HSV-1-positive cases to those
where HSV-1 was neither detected nor suspected with
respect to the severity of immunosuppression, a signifi-
cantly higher degree of immunosuppression in the HSV-
1-positive group was noted (p < 0.01, two-sided Mann-
Whitney analysis) (Figure 3B). This analysis was per-
formed including 56 of the 63 patients where reliable
information on maintenance immunosuppression was
available. In order to exclude selection bias, the compari-
son was also performed using the subgroup of 8 patients
that were proven to be HSV-1 negative by BAL. Albeit not
reaching the same level of significance, a similar trend was
observed with a similar median immunosuppression
severity score of 2.0 in the HSV-1 negative group (data not
shown). Though great caution must be applied in inter-
preting small numbers, it is intriguing that patients with
Wegener's Granulomatosis and vasculitis, who had the
strongest immunosuppression (score 3.3–3.5) also had a
HSV-1 positive BAL more often (15–25% of pneumonia/
pneumonitis) than Rheumatoid arthritis and SLE patients
(6–8% of pneumonia/pneumonitis) who were also on a
milder immunosuppressive regimen (score 1.5–1.6)
(Table 1).
Discussion
Patients with systemic autoimmune disease have an alter-
ation of immune responses that is due to both the action
of immunosuppressive treatment and to the underlying
condition itself [20,21]. They are at increased risk for
developing opportunistic infections among which respi-
ratory tract involvement is associated with potentially
adverse outcomes. Clinical workup of respiratory deterio-
Imaging study from Case 1 Figure 1
Imaging study from Case 1. A: Conventional chest radiograph with diffuse interstital pattern. B: High-resolution-CT 
(HRCT) featuring small pleural effusions and partial atelectasis of the right lower lobe in addition to distinctive ground-glass 
opacities. C: Fiberoptic bronchoscopy image showing a vulnerable tracheobronchial mucosa with multiple spontaneous bleed-
ing stigmata, consistent with generalized tracheobronchial inflammation.
Immunohistochemical staining for HSV-1 in a fixated cyot- spun obtained from BAL from Case 2 identifying a positive  cell (dark brown colour) Figure 2
Immunohistochemical staining for HSV-1 in a fixated 
cyotspun obtained from BAL from Case 2 identifying 
a positive cell (dark brown colour). Bottom and left: 
alveolar macrophages and lymphocytes with degenerative 
changes.BMC Pulmonary Medicine 2009, 9:22 http://www.biomedcentral.com/1471-2466/9/22
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ration in this setting is complicated by the fact that not
only bacterial, fungal or viral infectious agents but also a
pulmonary flare of the systemic disease or drug-related
pulmonary toxicity must be taken into the differential
diagnosis. Indicators that raise suspicion for HSV-1 pneu-
monitis in immunocompromised patients are severe res-
piratory insufficiency combined with pathologic findings
on imaging studies. Thoracic radiographs show segmental
bilateral opacities (~95%) and pleural effusions (~50%)
while CT may show ground-glass opacities (~100%), focal
consolidations (~75%), and pleural effusions (~88%)
[22,23]. Especially ground-glass opacities are a useful
diagnostic hint in the immunocompromised, suggesting
either an opportunistic infection due to Pneumocystis
jirovecii, CMV, HSV-1, or other viruses [24]. Other non-
infectious differential diagnoses of ground glass opacities
have been reviewed by [24].
HSV-1 pneumonitis is a diagnosis of exclusion relying on
clinical plausibility, positive viral testing, and imaging
studies. The definition of clinically relevant positive viral
testing is a matter of controversy. A recent study in
patients under prolonged mechanical ventilation by Luyt
et al. required the combination of (i) clinical deteriora-
tion, (ii) HSV-1 detection in the lower respiratory tract by
either PCR or culture, and (iii) cytological or histological
evidence of inclusion bodies from either BAL fluids or
biopsies to specifically define HSV-1 pneumonitis [9].
While viral cultures are difficult to handle, PCR of BAL flu-
ids has become the most popular diagnostic tool since it
is easily performed and sports a high sensitivity. Specifi-
city however, may be lacking due to potential contamina-
tion with fluids from oropharyngeal reactivation, which
may even occur in plain bacterial pneumonia [5,9,19,25].
Indeed, in Luyt's study, only 43% of those with a positive
PCR result also had cytological/histological evidence of
infection. Conversely, these cytological/histological crite-
ria lack sensitivity as illustrated by the fact that even open
lung biopsies may be negative in the case of autopsy-
proven HSV-1 pneumonitis [4]. From a theoretical point
of view, HSV-1 viraemia could be an additional specific
diagnostic tool, which is, again, associated with a marked
reduction in sensitivity [9].
A careful microbiological and remaining virological
workup is necessary to define by exclusion isolated HSV-1
pneumonitis. Unfortunately, results of bacterial sampling
are often falsely negative, be it due to inadequately low
amounts material, assay insensitivity or prior antibiotic
use, to name just a few. This is also illustrated by the 60%
of cases of pneumonia in our study in which no offending
agent was detected despite clinical evidence of infection.
A: Detected primary responsible (leading) infectious agents in 63 patients with ambulatory-acquired pneumonia/pneumonitis  and autoimmune disease Figure 3
A: Detected primary responsible (leading) infectious agents in 63 patients with ambulatory-acquired pneumo-
nia/pneumonitis and autoimmune disease. RSV = respiratoy syncytial virus. B: Immunosuppression scores were signifi-
cantly more severe in the 6 patients with HSV-1 detection in BAL than in those subjects without clinical or laboratory evidence 
for HSV-1 (as assessed for 56/63 patients with reliable information on immunosuppressive regimens available; ** p < 0.01, 
Mann-Whitney two-sided test).BMC Pulmonary Medicine 2009, 9:22 http://www.biomedcentral.com/1471-2466/9/22
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Hence, the possibility of falsely negative bacterial testing
also applies as a caveat to our Cases 1 and 2. Our centre
performed viral testing of BAL fluids for influenza rou-
tinely during winter. Concerning other viruses such as
adenovirus and coronavirus each centre should define a
standard in order to avoid omission or over-testing.
Viral load of BAL fluids detected by PCR correlates posi-
tively with the presence of cytology/histology-proven
HSV-1 pneumonitis and negatively with outcome
[6,9,16], but is not necessarily helpful in establishing the
diagnosis due to potentially great variations in sampling
conditions. However, it is intriguing that Case 1 in our
series who was on treatment with leflunomide showed a
viral load (9.750.000 Geq/ml) that was 3 and 13-fold
greater than the detected average (3.700.000) and median
(775.000) of all cases, respectively, while the clinical
course was prolonged (21 days prior to admission to hos-
pital) and comparatively mild. Leflunomide exhibits anti-
viral effects against HSV-1 by inhibiting the assembly of
viral capsids but not DNA-replication at dosages used in
rheumatic patients [26]. It is tempting to speculate, that
leflunomide might have led to the shedding of ill-assem-
bled virions in Case 1.
As outlined in the introduction, studies on HSV-1 pneu-
monitis in patients with various immunosuppressive con-
ditions are just beginning to emerge [27]. The present
study retrospectively analyzed admissions for pneumo-
nia/pneumonitis in a comparatively large cohort of out-
patients with autoimmune disease under a maintenance
regimen of immunosuppression. Although the considera-
ble limitations of a retrospective design must be borne in
mind, the data provide some perspective on the frequency
of HSV-1 and other bacterial, fungal and viral agents lead-
ing to pulmonary infection in this patient group.
Conclusion
Respiratory deterioration and pneumonia leading to hos-
pital admission was a common event in outpatients with
autoimmune diseases treated with current standard
immunosuppressive regimens. Acute life-threatening res-
piratory failure associated with the detection of HSV-1 in
the lower respiratory tract was a rare, but significant find-
ing. Based on our findings, diagnostic virological workup
in this particular patient cohort should include HSV-1
before starting, but without delaying treatment. In an area
of controversy [19,28], we provide further evidence that
immunocompromised patients may develop a condition
that is most accurately described as HSV-1 pneumonitis
and that appears amenable to treatment.
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